[
  {
    "uuid": "c74ad215c7253d8ea601ea46851e3327ca19ce45",
    "url": "https://leadership.ng/barau-preaches-unity-tolerance-perseverance-at-easter",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Sunday Isuwa",
    "published": "2024-03-29T00:00:00Z",
    "title": "Barau Preaches Unity, Tolerance, Perseverance At Easter",
    "text": "As Christians all over the world celebrate the death and resurrection of Jesus Christ at Easter, the Deputy Senate President, Senator Barau Jibrin, has",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Religion and Belief"
    ],
    "external_links": [
      "https://potentnaturalsolutions.com/brst-care/",
      "https://travads.com/l/leadershiptextmarch2024",
      "https://www.travads.com/l/leadershiptextmarch2024",
      "https://potentnaturalsolutions.com/brst-care",
      "https://www.potentnaturalsolutions.com/brst-care/"
    ],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "jesus christ",
          "sentiment": "negative"
        },
        {
          "name": "barau",
          "sentiment": "none"
        },
        {
          "name": "barau jibrin",
          "sentiment": "none"
        },
        {
          "name": "ismail mudashir",
          "sentiment": "none"
        },
        {
          "name": "christ",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "barau preaches unity",
          "sentiment": "negative"
        },
        {
          "name": "senate",
          "sentiment": "none"
        },
        {
          "name": "federal government",
          "sentiment": "none"
        }
      ],
      "locations": []
    },
    "rating": null,
    "crawled": "2024-03-29T12:31:28.266+03:00",
    "updated": "2024-03-29T13:50:26.052+03:00"
  },
  {
    "uuid": "a20b826f4b179f868559071fd6deb0d72f851805",
    "url": "https://posteezy.com/kristof-schoffling-monaco-41",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Poster",
    "published": "2024-09-26T16:35:00Z",
    "title": "Kristof Schöffling Monaco",
    "text": "<a href=\"https://movedigital.com/\n\">Kristof Schöffling Monaco</a>: Move Digital, founded by Kristof Schöffling, is getting ready to assist several family offices and governments in remaining on the cutting edge of technological developments. The veteran DLT firm has been keeping a close eye on the recent uptick in interest in numerous industries, including AI, the Metaverse and gaming, and Central Bank Digital Currencies (CBDCs). It has been decided that Move Digital will assist various European and Asian family offices in creating and deploying gaming and Metaverse applications. Family offices around the world are making frantic efforts to learn about and invest in these sectors due to the recent surge in interest. To help these offices make the most of their forays into these sectors, Move Digital is in a special position thanks to the depth of their knowledge in these areas. Melbourne, Tokyo, Zurich, London, and Monaco are just a few of the cities where Move Digital will collaborate with prestigious family offices.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "War, Conflict and Unrest",
      "Politics"
    ],
    "ai_allow": true,
    "webz_reporter": false,
    "external_links": [
      "https://movedigital.com/",
      "https://movedigital.com",
      "https://www.movedigital.com/"
    ],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-09-27T01:48:57.599+03:00",
    "updated": "2024-09-27T01:48:57.599+03:00"
  },
  {
    "uuid": "d8980db45e1a9a66a99efe9d060da087c1f532eb",
    "url": "http://stock.10jqka.com.cn/hks/20250731/c670038004.shtml",
    "ord_in_thread": 0,
    "author": "上海证券报·中国证券网",
    "published": "2025-07-31T03:45:00Z",
    "title": "麦济生物湖南湘江新区总部完成交付 乘创新药\"东风\"筹划赴港上市",
    "text": "上证报中国证券网讯(记者夏子航)7月29日，湖南麦济生物技术股份有限公司(以下简称“麦济生物”)位于世界计算.长沙智谷的总部办公室完成交付，标志着这家创新药研发领军企业加速落地湖南湘江新区。\n　　2024年初，在湘江新区管委会的统筹指导下，湘江国投联合园区招商部门紧密联动，通过“投资+招引”的方式将麦济生物从上海引入湘江新区。湘江国投通过湘江五号基金参与麦济生物两轮投资合计1.5亿元，持股比例达6.59%。\n　　在湘江新区的资金和政策支持下，麦济生物临床研发进展顺利，多管线进入临床三期阶段。随着企业向港交所递交上市申请书，麦济生物加快冲刺IPO。\n　　 麦济生物加速落地湖南湘江新区\n　　7月14日，麦济生物提交港股IPO申请。\n　　麦济生物成立于2016年，专注于发现、开发及商业化创新生物制剂，以解决有关过敏性及自身免疫疾病以及其他炎症与免疫性疾病方面尚未满足的医疗需求。\n　　招股书显示，自成立以来，麦济生物已自主研发并建立一条由八款创新候选产品组成的强大管线，包括核心产品MG-K10、关键产品MG-014及MG-013，以及五款其他候选产品。所有该等产品均为通过麦济生物自有技术平台发现及开发的新一代长效抗体。\n　　在8款候选产品中，3款目前处于临床阶段。其中，麦济生物核心产品MG-K10是一种潜在同类最佳、自主研发、处于注册临床阶段的长效抗IL-4Rα抗体，其独特的设计旨在通过抑制Th2信号通路，实现对中重度特应性皮炎、中重度哮喘等疾病的精准治疗。在已上市及处于临床开发阶段的长效抗IL-4Rα候选抗体中，MG-K10为唯一经过III期临床研究验证的长效抗IL-4Rα候选抗体，进度最快。\n　　根据弗若斯特沙利文的资料，抗IL-4Rα抗体是治疗中重度特应性皮炎及其他过敏性疾病的推荐疗法。美国食品药品监督管理局批准的首个抗IL-4Rα抗体——度普利尤单抗的数据显示，IL-4Rα靶向疗法可显著改善患者的生活质量，展现强大的临床治疗潜力。自2017年上市以来，度普利尤单抗目前仍为全球十大畅销药物之一，全球销量于2024年达到141亿美元。\n　　在特应性皮炎适应症方面，MG-K10的临床试验结果表明，其每4周一次、剂量为300mg的皮下注射方案(其他竞品需每2周注射一次)，不仅在安全性方面表现出色，而且在治疗效果上也取得了显著的成就。\n　　基于MG-K10在长效及安全方面显著的特点，麦济生物已与康哲药业达成在中国及新加坡的商业化合作协议。目前，该产品正在中国进行特应性皮炎的注册III期临床试验、哮喘的注册III期临床试验、结节性痒疹的注册III期临床试验及季节性过敏性鼻炎的II/III期临床试验。\n　　麦济生物创始人、总经理张成海十分看好湘江新区生物医药及大健康产业的发展前景。他表示，在长沙建设全球研发中心城市的号角下，生物医药研发型企业大有可为。未来将立足园区，在制药装备、临床研究等方面与本土企业开展产业协同合作，同时将建设研发中心，引领湘江新区抗体创新药的发展，为产业链上下游提供资源和助力。\n　　生物医药及大健康产业链作为湘江新区十大重点产业链之一，其总产值已突破860亿元。未来，湘江国投仍将围绕生物医药、信息技术等重点产业链开展投资布局，为湘江新区高质量发展贡献更多力量。\n　　 乘创新药“东风”筹划赴港上市\n　　近年来，我国创新药研发加速推进，且进一步拓展全球化。2025年第一季度，我国创新药license-out(对外授权)交易已有41起，总金额达369.29亿美元，已超过2024年上半年的交易总额。\n　　据了解，麦济生物已围绕MG-K10的核心抗体序列、制剂配方进行全球范围的专利布局。MG-K10的核心抗体序列专利在19个国家进行了专利申请，已获中国、美国和日本等的授权。MG-K10制剂配方专利已获得中国授权，通过PCT申请完成全球专利的布局。\n　　2025年7月11日，麦济生物完成Pre-IPO轮2.6亿元融资，投后估值达到26.4亿元。自设立以来，麦济生物累计融资6.74亿元，其重要股东既有地方政府的投资基金，又有知名的产业投资者。\n　　“在投资机构投资创新药企业时，会对公司进行严格的财务和法务尽调，创新药研发进度、前景以及专利的布局是否完备、是否有瑕疵，更是尽调过程中重点关注的领域。”熟悉麦济生物的产业投资者认为，麦济生物全球化的专利策略能够显著提升公司的市场竞争力和抗风险能力，为产品的国际化发展打下坚实的基础。\n　　据测算，从麦济生物的资金使用效率来看，扣除最近一轮融资，实质上麦济生物仅用5亿元左右的资金就开发出MG-K10这一核心产品，将其多个重磅适应症推进到了临床三期，并有除MG-K10之外的多个管线布局。\n　　“麦济生物目前的资金以及BD收到里程碑付款，足以支付其在研项目未来1、2年在国内的研发投入，随着资金储备的增加，除进一步完善管线布局及探索现有管线更多的适应症外，麦济生物还计划开展MG-K10多国多中心的临床试验，有望成为国内同靶点第一家开展涵盖美国、欧洲、日韩等多个国家和地区临床试验的企业。”一位创新药行业人士表示。",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "chinese",
    "sentiment": "positive",
    "categories": [
      "Economy, Business and Finance",
      "Science and Technology",
      "Health"
    ],
    "topics": [
      "Economy, Business and Finance->healthcare industry",
      "Economy, Business and Finance->business governance",
      "Economy, Business and Finance->business strategy and marketing",
      "Science and Technology->biotechnology",
      "Science and Technology->scientific innovation",
      "Science and Technology->medical research",
      "Health->health treatment and procedure",
      "Health->medical specialisation",
      "Health->health organisation"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": null,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "internal_images": [],
    "entities": {
      "persons": [],
      "locations": [],
      "organizations": []
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "top_news": [],
      "bias": null,
      "source": {
        "type": null,
        "city": null,
        "state": null,
        "country": null,
        "domain_type": null,
        "agency": null,
        "organization_name": null
      }
    },
    "rating": null,
    "crawled": "2025-07-31T07:48:29.855+03:00",
    "updated": "2025-07-31T07:55:14.000+03:00"
  }
]